P304: The Future of Investigator’s Brochure: Best Practices for Evolving Regulatory Requirements
Poster Presenter
Hema Kothari
Scientific Writer II
Bristol Myers Squibb United States
Objectives
To identify the challenges, enhance efficiencies, and streamline processes in the development of an Investigator’s Brochure (IB). This objective aims to implement best practices to ensure a high-quality, timely IB that meets regulatory requirements.
Method
Data collection included a survey to scientific writers, literature review, and document review. An open-ended, rating scale survey was distributed. A literature review consisted of regulatory guidelines and best practices. A document review measured key milestones for IB completion.
Results
The survey results highlighted key challenges in the development of IBs, including delays due to data availability, multiple document revisions, misalignment between stakeholders, inefficiencies in the document review process, difficulties in integrating diverse data sets, and challenges in managing cross-functional collaboration.
The literature review provided insight into evolving regulatory requirements and industry best practices. Guidelines from the International Council for Harmonisation (ICH) and European Clinical Trial Regulations (EU CTR) underscored the importance of well-structured, and concise IBs with timely updates.
The document review assessed IB completion timelines and identified critical milestones (ie, draft completion, review cycles, approval) contributing to delays.
Findings from the survey, literature and document review were combined to identify best practices for ensuring the development of a high-quality, timely IB. These best practices include early planning and collaboration with key stakeholders to define roles and responsibilities and establish timelines that help prevent delays. To improve efficiency, standardized template should be developed to ensure structured content development, clarity, and accuracy. The templates should be regularly updated to meet evolving regulatory requirements and align with other regulatory documents. Additionally, implementing a streamlined review process with clearly defined checkpoints minimizes unnecessary revisions, reduces misalignment between stakeholders, and accelerates completion timelines.
Conclusion
A well-defined and efficient process for developing an IB is critical. Scientific writers face several key challenges, including fostering collaboration among multiple stakeholders, ensuring accurate and up-to- date data, balancing scientific detail with clarity and conciseness, and providing timely updates, all while adapting to evolving regulatory requirements. By streamlining and enhancing efficiency throughout the various development stages of an IB can significantly improve document quality while also mitigating the process-related challenges.
An efficient IB development process can help accelerate clinical trial timelines, which is essential for faster drug development and market entry. Adopting best practices such as early planning and collaboration with key stakeholder, updating standardized templates to align with evolving regulatory requirements, and streamlining the review process, ensures the development of a high-quality IB while improving speed to completion.
